Evotec (OTCMKTS:EVTCY) vs. MindWalk (NASDAQ:HYFT) Head to Head Review

MindWalk (NASDAQ:HYFT) and Evotec (OTCMKTS:EVTCY) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Profitability

This table compares MindWalk and Evotec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Evotec	20.85%	16.02%	7.81%

Insider & Institutional Ownership

6.7% of MindWalk shares are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for MindWalk and Evotec, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	2	1	2.60
Evotec	0	0	0	0	0.00

MindWalk presently has a consensus price target of $5.00, suggesting a potential upside of 242.47%. Given MindWalk’s stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Evotec.

Valuation & Earnings

This table compares MindWalk and Evotec”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59 million	3.88	-$21.69 million	($0.20)	-7.30
Evotec	$572.16 million	1.13	$7.14 million	$0.41	4.78

Evotec has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MindWalk has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Evotec has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500.

Summary

Evotec beats MindWalk on 8 of the 15 factors compared between the two stocks.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

About Evotec

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.